The annual SLAS International Conference and Exhibition, held in Boston from February 7-11, 2026, served as a pivotal moment for…
Read More
Novo Nordisk Sues Hims for GLP-1 Patent Infringement
In a significant escalation of the ongoing battle over the burgeoning GLP-1 weight-loss drug market, pharmaceutical giant Novo Nordisk has…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…
Read More
FDA reverses course, agrees to review Moderna’s mRNA flu vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands Compared
The relentless pursuit of efficiency and patient safety in healthcare has driven a significant transformation within pharmacy operations, making the…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read More
Sai Life Sciences plans to recruit 700+ professionals in FY27 as Indian CRDMO demand accelerates
Sai Life Sciences, a prominent Contract Research, Development & Manufacturing Organization (CRDMO) based in Hyderabad, India, has announced an ambitious…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read MoreYOU MAY HAVE MISSED
